Study of acute HIV for investigating eradication strategies (stages)
Ended Project Grant Awarded Last action
- Award ID
- R56AI181653
- Recipient
-
The Regents Of The University Of California. San Francisco UEI KMH5K9V7S518
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $794,045
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Originally
- Place of performance
- California, USA
Award details come from USAspending.gov.
Description
- Abstract
- The goal of HIV cure research is to induce "antiretroviral therapy (art)-free" remission by eliminating persistent HIV to overcome the need for lifelong art and improve clinical outcomes associated with persistent HIV (increased inflammation- and aging-associated diseases). However, HIV cure trials have thus far failed to demonstrate a clinically meaningful reduction in the HIV reservoir size or lead to sustained art-free viral control. The goal of the proposed work is to address a critical need - to determine host in vivo mechanisms that drive HIV reservoir decay and sustain long-term viral control, identifying potential novel therapeutic candidates for HIV cure. We recently demonstrated that class II cytokines (specifically, IL-10 and type i and III interferons) exhibited ongoing fluctuations and predicted faster HIV reservoir decay during the first 24 weeks of art. These data support prior work demonstrating a dynamic and temporal role of type i interferons in controlling HIV/SIV infection and two recent studies that showed a critical role for IL-10 in the maintenance of the HIV/SIV reservoir. However, these other studies did not specifically evaluate the role of host cellular drivers of class II cytokine-mediated viral control across HIV stages: acute HIV infection (AHI), art initiation (arti), art suppression (art+), and art interruption (ATI). Our central hypothesis is that class II cytokines dynamically control virus at different stages of HIV. We aim to identify the host cellular drivers of class II cytokine-mediated viral control across HIV stages from 50 participants from our ucsf treat acute HIV cohort (diagnosed and initiated art
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $794,045 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Northwestern University | $217,517 | |
| J.david Gladstone Institutes | $183,708 |
Quick answers
Who received award R56AI181653?
R56AI181653 was awarded to The Regents Of The University Of California. San Francisco by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 1, 2024.
How much is award R56AI181653 worth?
$794,045 has been obligated on R56AI181653.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award